Swiss National Bank
SNDX icon

Swiss National Bank’s Syndax Pharmaceuticals SNDX Stock Holding History

Swiss National Bank’s Portfolio SNDX Stock Details SNDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.67M Buy
168,100
+6,700
+4% +$139K ﹤0.01% 1615
2026
Q1 		$3.77M Hold
161,400
– – ﹤0.01% 1509
2025
Q4 		$3.39M Buy
161,400
+2,900
+2% +$50.6K ﹤0.01% 1585
2025
Q3 		$2.44M Sell
158,500
-5,800
-4% -$75.9K ﹤0.01% 1754
2025
Q2 		$1.54M Buy
164,300
+14,900
+10% +$164K ﹤0.01% 1939
2025
Q1 		$1.84M Hold
149,400
– – ﹤0.01% 1817
2024
Q4 		$1.98M Hold
149,400
– – ﹤0.01% 1863
2024
Q3 		$2.88M Sell
149,400
-1,200
-0.8% -$24.8K ﹤0.01% 1649
2024
Q2 		$3.09M Hold
150,600
– – ﹤0.01% 1571
2024
Q1 		$3.58M Buy
150,600
+8,200
+6% +$183K ﹤0.01% 1507
2023
Q4 		$3.08M Buy
142,400
+21,400
+18% +$329K ﹤0.01% 1600
2023
Q3 		$1.76M Buy
121,000
+1,700
+1% +$32.2K ﹤0.01% 1920
2023
Q2 		$2.5M Buy
119,300
+3,600
+3% +$75K ﹤0.01% 1743
2023
Q1 		$2.44M Sell
115,700
-13,700
-11% -$341K ﹤0.01% 1716
2022
Q4 		$3.29M Buy
129,400
+16,100
+14% +$376K ﹤0.01% 1570
2022
Q3 		$2.72M Buy
113,300
+8,100
+8% +$182K ﹤0.01% 1662
2022
Q2 		$2.02M Buy
105,200
+11,800
+13% +$197K ﹤0.01% 1910
2022
Q1 		$1.62M Buy
93,400
+8,100
+9% +$136K ﹤0.01% 2151
2021
Q4 		$1.87M Hold
85,300
– – ﹤0.01% 2110
2021
Q3 		$1.63M Buy
85,300
+2,200
+3% +$36.7K ﹤0.01% 2181
2021
Q2 		$1.43M Buy
83,100
+9,000
+12% +$165K ﹤0.01% 2303
2021
Q1 		$1.66M Buy
74,100
+900
+1% +$20.3K ﹤0.01% 2119
2020
Q4 		$1.63M Buy
+73,200
New +$1.52M ﹤0.01% 2026

Other funds holding SNDX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Deerfield Management
Deerfield Management New York $9.6B AUM 113.36% 1-Year Est. Return
Eversept Partners
Eversept Partners New York $1.93B AUM 160.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Hood River Capital Management
Hood River Capital Management Palm Beach Gardens, Florida $13.8B AUM 163.97% 1-Year Est. Return

Swiss National Bank's SNDX Position: Q2 2026 in Review

Swiss National Bank increased its Syndax Pharmaceuticals (SNDX) stake by 4.2% in Q2 2026, buying an estimated $139K and bringing the position to 168,100 shares worth $3.67M. The position accounts for ﹤0.01% of the portfolio, ranked #1615.

Swiss National Bank first reported a position in SNDX in Q4 2020 and has held it in 23 quarters since. The position peaked at $3.77M in Q1 2026. 242 funds tracked by Wall St. Rank hold SNDX as of Q2 2026.

  • Swiss National Bank held 168,100 shares of Syndax Pharmaceuticals worth $3.67M as of Q2 2026.
  • Swiss National Bank bought 6,700 Syndax Pharmaceuticals shares in Q2 2026, an estimated $139K.
  • Syndax Pharmaceuticals made up ﹤0.01% of Swiss National Bank's portfolio in Q2 2026, its #1615 holding.
  • Swiss National Bank first reported a position in Syndax Pharmaceuticals in Q4 2020 and has held it in 23 quarters since.
  • Swiss National Bank's Syndax Pharmaceuticals position peaked at $3.77M in Q1 2026.
  • 242 funds tracked by Wall St. Rank held Syndax Pharmaceuticals as of Q2 2026.

Based on Swiss National Bank's 13F filing for Q2 2026, filed 11 Aug 2026.